PMC:7253235 / 42101-43184
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1371 | 111-115 | Gene | denotes | HER2 | Gene:2064 |
| 1372 | 117-121 | Gene | denotes | BRAF | Gene:673 |
| 1373 | 122-125 | Gene | denotes | MEK | Gene:5609 |
| 1379 | 38-46 | Species | denotes | patients | Tax:9606 |
| 1380 | 230-238 | Species | denotes | Patients | Tax:9606 |
| 1381 | 435-443 | Species | denotes | patients | Tax:9606 |
| 1382 | 797-804 | Species | denotes | patient | Tax:9606 |
| 1383 | 831-839 | Species | denotes | patients | Tax:9606 |
| 1408 | 31-37 | Disease | denotes | cancer | MESH:D009369 |
| 1409 | 81-87 | Disease | denotes | cancer | MESH:D009369 |
| 1410 | 250-264 | Disease | denotes | cardiotoxicity | MESH:D066126 |
| 1411 | 316-330 | Disease | denotes | cardiotoxicity | MESH:D066126 |
| 1412 | 552-566 | Disease | denotes | cardiotoxicity | MESH:D066126 |
| 1413 | 745-757 | Disease | denotes | dyslipidemia | MESH:D050171 |
| 1414 | 948-951 | Disease | denotes | CHF | |
| 1415 | 984-990 | Disease | denotes | cancer | MESH:D009369 |
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T118 | 859-863 | Body_part | denotes | face | http://purl.org/sig/ont/fma/fma24728 |
| T119 | 867-871 | Body_part | denotes | face | http://purl.org/sig/ont/fma/fma24728 |
| T120 | 909-914 | Body_part | denotes | blood | http://purl.org/sig/ont/fma/fma9670 |
| T121 | 924-929 | Body_part | denotes | lipid | http://purl.org/sig/ont/fma/fma67264 |
LitCovid-PD-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T55 | 859-863 | Body_part | denotes | face | http://purl.obolibrary.org/obo/UBERON_0001456 |
| T56 | 867-871 | Body_part | denotes | face | http://purl.obolibrary.org/obo/UBERON_0001456 |
| T57 | 909-914 | Body_part | denotes | blood | http://purl.obolibrary.org/obo/UBERON_0000178 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T422 | 31-37 | Disease | denotes | cancer | http://purl.obolibrary.org/obo/MONDO_0004992 |
| T423 | 81-87 | Disease | denotes | cancer | http://purl.obolibrary.org/obo/MONDO_0004992 |
| T424 | 745-757 | Disease | denotes | dyslipidemia | http://purl.obolibrary.org/obo/MONDO_0002525 |
| T425 | 948-951 | Disease | denotes | CHF | http://purl.obolibrary.org/obo/MONDO_0005009 |
| T426 | 984-990 | Disease | denotes | cancer | http://purl.obolibrary.org/obo/MONDO_0004992 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T310 | 605-612 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | testing |
| T311 | 859-863 | http://purl.obolibrary.org/obo/UBERON_0001456 | denotes | face |
| T312 | 867-871 | http://purl.obolibrary.org/obo/UBERON_0001456 | denotes | face |
| T313 | 909-914 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | blood |
| T314 | 909-914 | http://www.ebi.ac.uk/efo/EFO_0000296 | denotes | blood |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T117 | 122-125 | Chemical | denotes | MEK | http://purl.obolibrary.org/obo/CHEBI_28398 |
| T118 | 338-352 | Chemical | denotes | anthracyclines | http://purl.obolibrary.org/obo/CHEBI_48120|http://purl.obolibrary.org/obo/CHEBI_49322 |
| T120 | 924-929 | Chemical | denotes | lipid | http://purl.obolibrary.org/obo/CHEBI_18059 |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T235 | 31-37 | Phenotype | denotes | cancer | http://purl.obolibrary.org/obo/HP_0002664 |
| T236 | 81-87 | Phenotype | denotes | cancer | http://purl.obolibrary.org/obo/HP_0002664 |
| T237 | 745-757 | Phenotype | denotes | dyslipidemia | http://purl.obolibrary.org/obo/HP_0003119 |
| T238 | 948-951 | Phenotype | denotes | CHF | http://purl.obolibrary.org/obo/HP_0001635 |
| T239 | 984-990 | Phenotype | denotes | cancer | http://purl.obolibrary.org/obo/HP_0002664 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T267 | 0-227 | Sentence | denotes | Cardiotoxicity surveillance in cancer patients during and after treatment • Some cancer treatments (i.e., anti-HER2, BRAF-MEK treatments, clinical trials) require frequent surveillance of cardiac function (i.e., every 3 months) |
| T268 | 228-463 | Sentence | denotes | • Patients with known cardiotoxicity, or with known treatments that can cause long-term cardiotoxicity (i.e., anthracyclines, radiation) may not get timely surveillance imaging • Minimize cardiac imaging to patients who are symptomatic |
| T269 | 464-625 | Sentence | denotes | • Multidisciplinary discussion with hematologist/oncologist about reducing frequency of cardiotoxicity screening, especially if prior serial testing unremarkable |
| T270 | 626-699 | Sentence | denotes | • Limited imaging protocols to evaluate LVEF to minimize acquisition time |
| T271 | 700-804 | Sentence | denotes | • Defer primary prevention assessment (i.e., dyslipidemia management) unless critical to care of patient |
| T272 | 805-952 | Sentence | denotes | • Telemedicine visits for patients who do not require face-to-face assessment for medical issues (i.e., blood pressure/lipid management/stable CHF) |
| T273 | 953-1083 | Sentence | denotes | • Defer asymptomatic long-term cancer survivor surveillance (i.e., assessment of ventricular and valvular function) if no symptoms |